October 9, 2018
SciBac, a biotherapeutics company named to the 2018 CNBC Upstart 100 list. The Silicon Valley start-up shifts the paradigm on how to tackle superbugs. It is developing a microbe pill to boost the body's microbiome in the gut, lungs and skin to kill bacteria that cause antibiotic-resistant disease.
October 9, 2018
SciBac is on CNBC's Upstart 100 list -- promising global startups to watch in 2018, that are "breaking industry barriers on the path to becoming tomorrow's household names."
September 20, 2018
CARB-X’s annual report highlights SciBac’s important contribution to the fight against antibiotic resistance.
September 12, 2018
July 31, 2018
SciBac has been awarded up to $3.76 million in non-dilutive funding by CARB-X, a public-private partnership devoted to accelerating early medical R&D to combat the rising threat of antibiotic resistant Superbugs. This award supports development of SciBac’s novel biotherapeutic to treat and prevent Clostridium difficile infections (CDI).
January 28, 2018
Learn all about CEO Jeanette Mucha, the story of how SciBac was founded, MERGE technology, and the biotherapeutic pipeline that harnesses the microbiome to tackle antibiotic resistant diseases.
January 27, 2018
SciBac to present at 11:15 am, March 30 2018 at UCLA California Nanosystems Institute, Los Angeles, CA.
January 1, 2018
SciBac CEO, Jeanette Mucha, to present at the Biotech Showcase™ Annual Conference on January 10, 2018, 1:45pm at Hilton Union Square, Room Franciscan - A.
September 19, 2017
U.S. patent just issued for SciBac's "Method for Producing Chimeric Microbial Hybrids."
July 18, 2017
SciBac will use its MERGE technology platform to develop non-GMO hybrid microorganisms for the purpose of creating a cost-efficient expression of enzymes for Novozymes.
May 3, 2017
Empowering the Cutting-Edge Companies of Tomorrow, Today SciBac announced as a finalist, having been judged by experts with entrepreneurial, investment, start-up, economic development, capital formation, and academic backgrounds from both the public and private sectors.
Apr 13, 2017
Jeanette Mucha, CEO of SciBac, said: “The Breakout Labs grant will allow us to further advance our C. diff program, developing a live biotherapeutic that can destroy the harmful C. diff pathogen without antibiotics, while nurturing a healthy gut microbiome.”